The Company Behind Millions of Pairs of Glasses
By Alexander Fernandez
Reporter, Life News Today
Millions of people wear glasses connected in some way to EssilorLuxottica, the world's largest eyewear company. That reach has fueled a long-standing claim that the Del Vecchio family controls most of the eyewear industry. Through Delfin, its Luxembourg holding company, the family owned slightly more than 32% of EssilorLuxottica at the end of 2024, making it the company's largest shareholder. Public records, corporate filings and regulatory reviews examined show that, while the family does not own most of the global eyewear industry, EssilorLuxottica's vertically integrated business extends across brands, lenses, laboratories, retail chains and vision benefits, giving the company an influence that reaches multiple stages of a single eyewear purchase.
EssilorLuxottica operates across nearly every level of the eyewear business. According to its 2025 annual report, the company owns brands including Ray-Ban, Oakley and Persol, produces eyewear under licenses from luxury companies such as Prada, Chanel and Versace, supplies independent optical stores and operates retailers including LensCrafters, Sunglass Hut, Pearle Vision and Target Optical. It also owns EyeMed, one of the nation's largest vision benefits administrators, which manages vision insurance plans that help determine how millions of Americans pay for eye exams, eyeglasses and contact lenses. Together, those businesses represent only part of a portfolio that spans more than 150 proprietary and licensed brands. EssilorLuxottica reported 17,750 stores worldwide and 28.49 billion euros, approximately $32.2 billion, in 2025 revenue. Its vertically integrated structure extends from manufacturing and laboratories to retail stores and vision benefits, helping explain why many consumers perceive the company as controlling far more of the eyewear business than its ownership stake alone would suggest.
A long-running claim that the family controls 80% of eyewear began circulating in 2012. Forbes contributor Dean Crutchfield applied the figure to “major eyewear brands” without defining which brands qualified or identifying a regulatory finding or global market calculation behind it. Later retellings expanded the claim into ownership of the eyewear market and then the entire industry. No regulatory decision, corporate filing or documented industry calculation reviewed showed that Luxottica or EssilorLuxottica owned or controlled 80% of the industry. The scale behind the claim was real, even if the percentage was not. When 60 Minutes correspondent Lesley Stahl asked how many people worldwide were wearing Luxottica glasses in 2012, then-Chief Executive Andrea Guerra answered, “At least half a billion are wearing our glasses now.” That extraordinary reach helps explain why the company is often perceived as controlling more of the eyewear industry than corporate ownership records show.
“EssilorLuxottica is ingrained in the eyeglass industry,” said Paul, a Fairfax optician who requested that his last name and company not be disclosed. He described EssilorLuxottica and private equity as “two different beasts.” Private equity, he said, is “trying to actually own storefronts, making their own lenses and everything.” He called large chains “cookie cutter,” while independent stores work with “a large variety of labs and providers.”
Leonardo Del Vecchio founded Luxottica in 1961 as a small workshop producing components for other eyewear companies, according to the company’s SEC-filed history. Luxottica presented its first prescription-eyewear collection in 1971 and acquired Italian distributor Scarrone in 1974, a purchase it described as its first step toward vertical integration. The company entered North American optical retail by acquiring LensCrafters in 1995, Ray-Ban in 1999 and Oakley in 2007.
The 2018 merger with Essilor connected Luxottica's frame, distribution and retail operations with Essilor's prescription-lens manufacturing and optical technology. "Finally, after fifty years, two products which are naturally complementary, namely frames and lenses, will be designed, manufactured and distributed under the same roof," Del Vecchio, then Luxottica's executive chairman, said in the companies' 2017 merger announcement. The combined company now participates in nearly every stage of the eyewear process. It develops lens materials, coatings and optical designs while supplying the equipment and laboratory services used to cut, treat and fit lenses into frames. Its wholesale business supplies independent optical retailers, while company-owned stores and websites sell directly to consumers. Through EyeMed, the company also administers vision-benefit networks, provider reimbursements and consumer allowances. In recent years, EssilorLuxottica has expanded further into eye-care clinics and diagnostic technologies, extending its presence to stages of the patient experience that occur even before a customer reaches the retail counter.
Federal regulators examined whether the combined company could raise lens prices or deny products to independent eye-care providers, potentially directing patients toward Luxottica-owned stores. After reviewing more than 1 million documents and interviewing more than 100 market participants, the FTC concluded that independent providers had alternative suppliers. The FTC also found that Luxottica accounted for less than 10% of national optical retail sales, limiting its ability to recover lost wholesale business through its own stores. The European Commission allowed the merger to proceed after examining lenses, frames, sunglasses and optical retail outlets and seeking feedback from nearly 4,000 opticians. European regulators concluded that the combined company lacked the ability or financial incentive to exclude competing suppliers through practices such as tying or bundling. Those merger reviews addressed whether combining Essilor and Luxottica was likely to reduce competition across the markets the agencies examined.
Later regulatory actions in France and Turkey examined specific business practices in their domestic markets after the merger, rather than reconsidering whether the transaction itself should have been approved. Neither type of decision concluded that the Del Vecchio family or EssilorLuxottica owned a majority of the global eyewear industry. France’s competition authority found that Essilor restricted lens deliveries, branding permissions and warranty coverage for online sellers while treating physical retailers differently. The authority concluded that Essilor abused its dominant position in the French wholesale corrective-lens market between 2009 and 2020 and obstructed lower-priced online competition. It imposed fines totaling more than 81 million euros, and a Paris appeals court upheld the decision in December 2024. Turkey’s competition authority examined agreements connecting ophthalmic lenses with lens-cutting equipment. In 2023, the authority found that the arrangements created de facto exclusivity, excluded competitors and violated commitments imposed when Turkey conditionally approved the merger in 2018. The finding concerned those agreements in Turkey, not ownership of the worldwide eyewear industry.
EssilorLuxottica is not the only company operating across several parts of the eyewear business. VSP administers vision benefits, runs optical laboratories, owns frame makers Marchon and Altair, and operates Eyeconic and Visionworks. Its 2025 acquisitions of Eyemart Express and Marcolin added nearly 250 stores, many with in-house laboratories, and another major frame designer and distributor. Kering Eyewear, Safilo, Warby Parker, National Vision and independent optical businesses also compete in portions of the market. National Vision, the operator of America’s Best and Eyeglass World, described U.S. optical retail as fragmented in its 2025 annual report and said independent retailers still represented nearly half the industry.
A single eyewear purchase may involve a lens supplier, laboratory, vision-benefit administrator and retailer, and some of those businesses may share a corporate owner. The Government Accountability Office reported in 2026 that vision-insurance markets showed significant concentration, while comprehensive data on vertical integration remained unavailable. It found no peer-reviewed studies from the previous decade measuring the effects of combining insurance, manufacturing and retail. “We don’t really know what effects a highly concentrated market for dental or vision could have on Americans,” the GAO wrote in a March 10, 2026, public summary of its findings.
As more stages of eye care have been brought together under one corporate structure, consumer advocates and federal regulators have questioned whether patients clearly understand that an eye examination and the purchase of eyewear are separate transactions. Felecia P. Neilly, a Georgia consumer who testified during a 2023 Federal Trade Commission workshop, said she had assumed she needed to buy glasses from the provider who conducted her examination. “I thought you always needed to get your eyeglasses from the provider,” she said. After receiving her prescription and shopping online, she found significantly lower prices.
An eye examination and an eyewear purchase are separate services, even when insurance covers both during the same visit. The final transaction can include the examination, frame, lenses, coatings, insurance allowance and the balance paid by the patient. Dr. Artis Beatty, MyEyeDr.'s chief medical officer, described the process from inside a national practice during the FTC's May 18, 2023, workshop. Patients may have insurance for both the examination and eyewear and often prefer to make one payment, he told regulators. "Having to break it into pieces can make it a little bit more confusing," Beatty said. To reinforce that patients may purchase eyewear from a different seller, the FTC's 2024 revision of the Eyeglass Rule requires prescribers to give patients a copy of their prescription and retain a signed or digital record confirming its release. The change strengthened a consumer's ability to take a prescription elsewhere, but it did not address shared ownership among manufacturers, laboratories, benefit administrators and retailers involved after the examination.
Although EssilorLuxottica's reach across the eyewear business is well documented, the broader effects of that vertical integration remain the subject of limited independent research. Regulators have examined specific mergers and business practices, but comprehensive evidence measuring the long-term effects of combining manufacturing, laboratories, vision benefits and retail under common ownership remains limited. The available evidence documents a company whose influence comes from participating in multiple stages of the eyewear business rather than from owning the industry itself. From the eye examination and vision benefits to lenses, laboratories and retail stores, EssilorLuxottica can be involved at multiple points in a single eyewear purchase, a position few competitors can match.
Comments